Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Treasury Shares: 2023-2024

Historic Treasury Shares for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $112,159.

  • Monte Rosa Therapeutics' Treasury Shares rose 590.69% to $774,675 in Q3 2025 from the same period last year, while for Sep 2025 it was $774,675, marking a year-over-year increase of 590.69%. This contributed to the annual value of $112,159 for FY2024, which is 52.58% down from last year.
  • Monte Rosa Therapeutics' Treasury Shares amounted to $112,159 in FY2024, which was down 52.58% from $236,519 recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Treasury Shares ranged from a high of $236,519 in FY2023 and a low of $112,159 during FY2024.
  • For the 2-year period, Monte Rosa Therapeutics' Treasury Shares averaged around $174,339, with its median value being $174,339 (2023).
  • Data for Monte Rosa Therapeutics' Treasury Shares shows a maximum YoY plummeted of 52.58% (in 2024) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' Treasury Shares (Yearly) stood at $236,519 in 2023, then tumbled by 52.58% to $112,159 in 2024.